The inclusion criteria are a preoperative IIEF-5 of 22-25, preoperative FT value, and IIEF5 at 3 and 15 months post-surgery. The cohort was then divided into three categories: FT<5.1, 5.1≤FT≤7, and FT>7. FT was graphed based on the percentage of potency over postoperative (3, 9, and 15) months. Dr. El-khatib highlighted that at 15 months patients with FT<5.1, 5.1≤FT≤7, and FT>7, had 81.3%, 88.0%, 90.3% potency respectively.
Dr. El-khatib concludes FT levels less than 5.1ng/dL had a decreased return at all of the varying time points. The recommendation is to consider these certain patients for testosterone therapy.
Presented by: Farouk M. El-khatib, MD, University of California, Irvine, Department of Urology
Co-authors: Farouk M. El-khatib, Linda Huynh, Maxwell Towe, Faysal A Yafi, Thomas Ahlering
Affiliation: University of California, Irvine
Written by: Joshua Tran, (Department of Urology, University of California-Irvine) at the American Urological Association's 2019 Annual Meeting (AUA 2019), May 3 – 6, 2019 in Chicago, Illinois